Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915

NOVO NORDISK AS

(NOVO B)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : Says All Production Plants Will Run on Renewable Power by 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/24/2015 | 04:13am EST
   By Dominic Chopping 
 

Danish insulin manufacturer Novo Nordisk A/S (NVO) said Tuesday it aims to use only electricity from renewable sources at all of its global production sites by 2020, after it recently joined a collaborative of global businesses committed to using 100% renewable electricity.

At present, the company's production sites in Denmark, Brazil and Japan use electricity from renewable sources and last month its Tianjin production site in China signed an agreement to purchase electricity from a windmill farm in Inner Mongolia. Other production sites in the US, France, Russia, Algeria and Iran will enter similar agreements in the coming years, it said.

Henrik Wulff, executive vice president and head of Novo Nordisk Product Supply, said "Switching to renewable electricity makes sense from both a climate and a cost perspective. As more companies invest in renewable electricity, the technology is likely to get even more efficient and less costly."

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @domchopping @WSJNordics

Stocks mentioned in the article
ChangeLast1st jan.
EURO / BRAZILIAN REAL (EUR/BRL) -1.37% 4.5855 Delayed Quote.5.03%
NOVO NORDISK AS -0.40% 383.95 Delayed Quote.29.41%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVO NORDISK AS
12/02NOVO NORDISK : Disclosure of transaction data
PU
12/02NOVO NORDISK : A/S - Share repurchase programme
PU
11/26NOVO NORDISK : There are eight million people with diabetes in the philippines
AQ
11/25NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20NOVO NORDISK : and UNICEF announce new partnership to help prevent childhood ove..
AQ
11/20NOVO NORDISK : and UNICEF announce new partnership to help prevent childhood ove..
PU
11/20Novo Nordisk expects to meet its current long-term financial targets and intr..
GL
11/19NOVO NORDISK A/S : Share repurchase programme
AQ
11/18Dicerna Shares Rise on Collaboration With Novo Nordisk
DJ
11/18DICERNA PHARMACEUTICALS : Novo Nordisk to Collaborate on Liver Disorders
DJ
More news
Financials (DKK)
Sales 2019 121 B
EBIT 2019 52 470 M
Net income 2019 39 012 M
Finance 2019 13 739 M
Yield 2019 2,21%
P/E ratio 2019 23,4x
P/E ratio 2020 20,5x
EV / Sales2019 7,38x
EV / Sales2020 6,92x
Capitalization 904 B
Chart NOVO NORDISK AS
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 381,37  DKK
Last Close Price 383,95  DKK
Spread / Highest target 22,4%
Spread / Average Target -0,67%
Spread / Lowest Target -41,9%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS29.41%134 818
JOHNSON & JOHNSON8.14%367 304
ROCHE HOLDING AG25.10%263 429
MERCK AND COMPANY16.15%225 956
PFIZER-12.88%210 463
NOVARTIS21.74%207 450